<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, March 1, 2018 (HealthDay News) — Strains of Staphylococcus epidermidis<\/i> producing 6-N<\/i>-hydroxyaminopurine (6-HAP) may provide protection against skin neoplasia, according to research published online Feb. 28 in Scientific Advances<\/i>.<\/p>\n
Teruaki Nakatsuji, Ph.D., from the University of California in San Diego, and colleagues report on the discovery that strains of S. epidermidis<\/i> produce 6-HAP which inhibits DNA polymerase activity. The authors describe results of a continued analysis of 6-HAP in culture, and in mice and humans.<\/p>\n
The researchers found that 6-HAP selectively inhibited proliferation of tumor lines in culture, but did not inhibit primary keratinocytes. Resistance to 6-HAP correlated with mitochondrial amidoxime reducing component expression; these enzymes were not seen in cells sensitive to 6-HAP. In mice, intravenous injection of 6-HAP suppressed B16F10 melanoma growth, with no indication of systemic toxicity. Compared with mice colonized with a control S. epidermidis<\/i> strain that did not produce 6-HAP, colonization of mice with a 6-HAP-producing strain reduced the incidence of ultraviolet-induced tumors. Multiple healthy human subjects had S. epidermidis<\/i> strains producing 6-HAP.<\/p>\n
“These findings show a new role for skin commensal bacteria in host defense,” the authors write.<\/p>\n
Two authors are co-inventors on a patent relating to the bacterial antiproliferative compound; one author disclosed financial ties to the biopharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n